Propanc CEO James Nathanielsz said the crypto treasury would assist a “transformative phase” for the company by strengthening its balance sheet and advancing its proenzyme-based oncology platform.
“We can target not only patients suffering from metastatic cancer from solid tumors, but several chronic diseases based upon the mechanism of action of proenzyme therapy.”
While Propanc didn’t say which digital assets it plans to buy for its crypto treasury, Hexstone’s clients have invested in everything from Bitcoin ($BTC), Ether (ETH), Solana (SOL), Injective (INJ) as well as some lesser-known cryptocurrencies.
Biotech companies adopting a crypto strategy
Propanc joins Sonnet BioTherapeutics, Sharps Technology and other biotech companies that have turned to crypto to reignite investor interest.
However, Propanc’s move was not received well by its investors, with PPCB shares diving 10.5% on the Nasdaq on Monday, according to Yahoo Finance data.
PPCB shares are now down 46.7% over the last month. Source: Yahoo Finance
Crypto treasury strategies haven’t fared well lately
Bitcoin treasury holding companies have lost some of their sheen over the last few months as more companies flood into the space.
Related: ‘Most hated bull run ever?’ 5 things to know in Bitcoin this week
Even Strategy, the largest corporate Bitcoin holder, has seen its market cap slide over 43% from $122.1 billion in July to $69.1 billion today.
Metaplanet, one of the best-performing stocks on the Tokyo Stock Exchange to start the year, has been hit even harder, falling around 55% since late June, while other Bitcoin treasury companies have even had to offload some of their $BTC holdings to pay outstanding debt.
Magazine: Bitcoin OG Kyle Chassé is one strike away from a YouTube permaban